Masimo Corp. (MASI) EVP Sells $590,000.00 in Stock
Masimo Corp. (NASDAQ:MASI) EVP Thomas Samuel Mcclenahan sold 10,000 shares of the stock in a transaction dated Friday, September 30th. The stock was sold at an average price of $59.00, for a total transaction of $590,000.00. Following the sale, the executive vice president now owns 10,000 shares in the company, valued at $590,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Masimo Corp. (NASDAQ:MASI) opened at 59.24 on Wednesday. The stock has a 50 day moving average of $58.98 and a 200-day moving average of $51.21. Masimo Corp. has a 1-year low of $33.03 and a 1-year high of $60.52. The firm has a market capitalization of $2.92 billion, a P/E ratio of 31.06 and a beta of 0.70.
Masimo Corp. (NASDAQ:MASI) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported $0.57 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.16. The company had revenue of $172.64 million for the quarter, compared to the consensus estimate of $166.02 million. Masimo Corp. had a net margin of 15.40% and a return on equity of 29.07%. The firm’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.36 EPS. On average, equities analysts expect that Masimo Corp. will post $2.02 earnings per share for the current year.
A number of brokerages have issued reports on MASI. BTIG Research reiterated a “hold” rating on shares of Masimo Corp. in a research note on Friday, August 5th. Zacks Investment Research downgraded shares of Masimo Corp. from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Piper Jaffray Cos. reiterated an “overweight” rating and set a $55.00 price objective (up from $52.00) on shares of Masimo Corp. in a research note on Friday, August 5th. Finally, Wedbush reiterated an “outperform” rating and set a $63.00 price objective (up from $60.00) on shares of Masimo Corp. in a research note on Thursday, August 4th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $52.60.
Several institutional investors have recently modified their holdings of the company. First Republic Investment Management Inc. bought a new position in shares of Masimo Corp. during the first quarter worth $12,638,000. Henderson Group PLC increased its position in shares of Masimo Corp. by 57.6% in the second quarter. Henderson Group PLC now owns 725,066 shares of the company’s stock worth $38,077,000 after buying an additional 265,011 shares during the period. BlackRock Advisors LLC increased its position in shares of Masimo Corp. by 49.7% in the second quarter. BlackRock Advisors LLC now owns 741,931 shares of the company’s stock worth $38,962,000 after buying an additional 246,358 shares during the period. Numeric Investors LLC bought a new position in shares of Masimo Corp. during the second quarter worth $12,366,000. Finally, Columbus Circle Investors bought a new position in shares of Masimo Corp. during the second quarter worth $9,000,000. 79.88% of the stock is currently owned by institutional investors.
About Masimo Corp.
Masimo Corporation is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring.
Receive News & Stock Ratings for Masimo Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corp. and related stocks with our FREE daily email newsletter.